AXQ Capital LP Takes $863,000 Position in Doximity, Inc. (NASDAQ:DOCS)

AXQ Capital LP bought a new stake in shares of Doximity, Inc. (NASDAQ:DOCS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,162 shares of the company’s stock, valued at approximately $863,000.

Several other hedge funds have also recently made changes to their positions in DOCS. KBC Group NV increased its stake in shares of Doximity by 22.9% during the third quarter. KBC Group NV now owns 3,296 shares of the company’s stock valued at $144,000 after buying an additional 614 shares during the period. Natixis Advisors LLC increased its stake in shares of Doximity by 43.5% during the third quarter. Natixis Advisors LLC now owns 31,815 shares of the company’s stock valued at $1,386,000 after buying an additional 9,644 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Doximity by 5.0% during the third quarter. Thrivent Financial for Lutherans now owns 30,991 shares of the company’s stock valued at $1,350,000 after buying an additional 1,474 shares during the period. Prospera Private Wealth LLC purchased a new position in shares of Doximity during the third quarter valued at approximately $133,000. Finally, Commerce Bank purchased a new stake in Doximity in the third quarter worth $314,000. 87.19% of the stock is owned by hedge funds and other institutional investors.

Doximity Stock Up 0.4 %

DOCS stock opened at $63.01 on Friday. Doximity, Inc. has a twelve month low of $22.96 and a twelve month high of $85.21. The stock has a market cap of $11.76 billion, a P/E ratio of 63.01, a PEG ratio of 4.10 and a beta of 1.34. The business’s 50-day moving average price is $64.42 and its 200-day moving average price is $53.39.

Insider Activity at Doximity

In related news, Director Timothy S. Cabral sold 20,000 shares of Doximity stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now owns 6,360 shares of the company’s stock, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 37.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have issued reports on DOCS. Needham & Company LLC increased their price objective on Doximity from $65.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Piper Sandler upgraded Doximity from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $31.00 to $78.00 in a report on Friday, February 7th. Wells Fargo & Company restated an “equal weight” rating on shares of Doximity in a report on Friday, February 7th. Bank of America raised their price target on Doximity from $54.00 to $57.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Finally, Canaccord Genuity Group raised their price target on Doximity from $60.00 to $71.00 and gave the company a “hold” rating in a report on Friday, February 7th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Doximity has an average rating of “Moderate Buy” and an average target price of $64.22.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.